Asset
ENDOXIFEN
ATOSSA THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05607004 | phase2 | active_not_recruiting | 2023-02-14 | 2026-11-01 | Atossa Therapeutics, Inc. | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer |
| NCT07869732 | phase2 | not_yet_recruiting | 2027-03-01 | 2028-06-01 | Atossa Therapeutics, Inc. | (Z)-Endoxifen in Girls With MAS-Associated Peripheral Precocious Puberty |
FDA applications (0)
This company has no applications containing this asset.